Filing Flows

Filing Flows › 8-K events › Axsome Therapeutics

Axsome Therapeutics: results of operations

Form 8-K filed Nov 2, 2026 · items 2.02, 8.01

FDA decisionsAxsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

What the filing says

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth

ScaleThe filing names $259.7M: about 25% of Axsome Therapeutics' annual revenue ($1.04B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

Axsome Therapeutics at a glance

Latest quarterQ3 2026
Revenue$259.7M
Revenue Y/Y+52%
Operating margin-4.3%
IndustryPharmaceutical Preparations

Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%. The chart follows the revenue to costs, profit and cash.

Axsome Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.